Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Lipocine Inc.

Get SEC filing alerts via email and in your feed for Lipocine Inc.

LPCN

Lipocine Inc.

About Lipocine Inc.

Lipocine Inc. is a biopharmaceutical company specializing in oral delivery of challenging molecules using its proprietary Lip’ral platform. Its focus includes developing treatments for CNS disorders, hormone replacement, liver diseases, and obesity management. The company’s portfolio features innovative oral drug candidates and licensed products like TLANDO for testosterone therapy, targeting high unmet medical needs globally through strategic licensing and partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Lipocine Inc.

1
1
Lipocine Inc. Lipocine Inc. Reports 27% Revenue Growth but Increased Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Lipocine Inc. Lipocine Inc. Reports Revenue Decline to $1.98 Million and Increased Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Lipocine Inc. Lipocine Inc. Reports 89% Revenue Decline in Q3 2025, Net Loss of $3.2 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Lipocine Inc. Lipocine Inc. Reports Q2 2025 Financial Results with Revenue Increase and Net Loss Reduction

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Lipocine Inc. Lipocine Inc. Reports Significant Revenue Decline and Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Lipocine Inc. Lipocine Inc. Reports $11.2 Million Revenue for Fiscal Year 2024, Net Income Recovery

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Lipocine Inc. Lipocine Reports Significant Revenue Growth, Net Loss Improvement in 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments